Every Form 4 that Cardio Diagnostics Holdings Inc (CDIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CDIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDIO filings page.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options as part of his compensation. On June 30, 2026, he was awarded 2,854 stock options with a conversion price of $2.19 per share, each option representing the right to buy one share of common stock. These are classified as a grant or award, not an open-market purchase or sale. Following this award, Fung holds a total of 12,367 stock options linked to Cardio Diagnostics common stock, giving him additional potential future ownership if he chooses to exercise the options before they expire in 2036.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts received a grant of stock options covering 2,854 shares of common stock. The options have an exercise price of $2.19 per share and expire on June 30, 2036. This is a compensation-related award, not an open-market trade, and brings her directly held option awards to a total of 12,367 underlying shares.
Cardio Diagnostics Holdings director James Intrater received a new stock option grant as part of his compensation. On June 30, 2026, he was granted options to acquire 2,854 shares of common stock at an exercise price of $2.19 per share, expiring on June 30, 2036. After this award, he directly holds options for 13,318 shares in total.
Cardio Diagnostics Holdings director Burton Paul Frederick received a grant of stock options, providing additional equity-based compensation. The award covers 2,854 options to buy Common Stock at an exercise price of $2.19 per share, expiring on June 30, 2036. Following this grant, Frederick holds 13,318 stock options directly.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options for 3,205 shares of Common Stock at an exercise price of $1.95 per share on March 31, 2026. Following the grant, he holds stock options for a total of 9,513 shares, expiring on March 31, 2036.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts received a grant of stock options covering 3,205 shares of Common Stock. The options have an exercise price of $1.95 per share and expire on March 31, 2036. Following this award, she directly holds 9,513 stock options.
Intrater James reported acquisition or exercise transactions in this Form 4 filing.
Cardio Diagnostics Holdings director James Intrater received a grant of 3,205 stock options on Common Stock at $1.95 per share. These options were granted on March 31, 2026 and expire on March 31, 2036. Following the award, he holds 10,464 stock options directly.
Cardio Diagnostics Holdings director Burton Paul Frederick received a grant of stock options as compensation. He was awarded 3,205 options to buy Common Stock at an exercise price of $1.95 per share, expiring on March 31, 2036. Following this grant, he holds 10,464 derivative securities directly.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung reported receiving a grant of stock options. On 12/31/2025, he was awarded options to buy 2,306 shares of common stock at an exercise price of $2.71 per share. After this grant, he beneficially owns a total of 6,308 stock options directly. This filing records the equity compensation awarded to a board member and does not involve any sale of shares.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts reported a stock option grant. On December 31, 2025, she was awarded 2,306 stock options with a right to buy common stock at an exercise price of $2.71 per share. After this grant, she beneficially owns 6,308 derivative securities in the form of stock options, held with direct ownership.
Cardio Diagnostics Holdings, Inc. director Burton Paul Frederick reported a new stock option award. On 12/31/2025, he was granted 2,306 stock options (right to buy common stock) with a conversion or exercise price of $2.71 per share. After this grant, he beneficially owns 7,259 derivative securities in the form of stock options, held in direct ownership. The filing was made on Form 4 for a single reporting person, reflecting an option grant coded as an acquisition.
Peter Fung, a director of Cardio Diagnostics Holdings, Inc. (CDIO), reported a non-derivative change tied to stock options dated 09/30/2025. The filing shows 1,559 stock options were acquired with an exercise price of $4.01, exercisable immediately and expiring on 09/30/2035. After the transaction, Mr. Fung beneficially owned 4,002 shares of common stock on a direct basis.
Director Wendy J. Betts reported acquiring 1,559 stock options of Cardio Diagnostics Holdings, Inc. (CDIO) on 09/30/2025. The options have an exercise price of $4.01, are exercisable immediately (09/30/2025) and expire on 09/30/2035. The filing shows these options cover 1,559 underlying shares, and following the reported transaction Ms. Betts beneficially owns 4,002 shares of common stock. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025. The report is a Section 16 disclosure of insider changes in beneficial ownership and contains no additional financial results or contractual terms beyond the option details.
James Intrater, a director of Cardio Diagnostics Holdings, Inc. (CDIO), exercised 1,559 stock options on 09/30/2025 at an exercise price of $4.01 per share, converting those options into 1,559 shares of common stock. After the transaction he directly beneficially owns 4,953 shares. The Form 4 reports this routine equity award exercise and shows the resulting direct ownership level.
Paul Burton, a director of Cardio Diagnostics Holdings, Inc. (CDIO), exercised stock options on 09/30/2025 to acquire 1,559 shares at an exercise price of $4.01 per share. The options are exercisable immediately and expire on 09/30/2035. Following the reported transaction, Mr. Burton beneficially owns 4,953 shares of common stock. The Form 4 was filed via signature by Elisa Luqman as attorney-in-fact on 10/03/2025. The filing identifies the reporting person as a director and shows the ownership form as direct.